Cue Biopharma (CUE) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Cue Biopharma (CUE) over the past year, gaining 62.9% versus a loss of 13.2%. Over five years, WHWK leads with a -87.2% price change compared with -94.1% for CUE. Cue Biopharma is the larger company by market cap ($200.9 million vs $200.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | WHWK |
|---|---|---|
| Share price | $27.66 | $3.52 |
| Market cap | $200.93M | $200.67M |
| 1-day change | +23.87% | +1.44% |
| YTD return | +144.04% | +43.39% |
| 1-year return | -13.25% | +62.91% |
| 5-year return | -94.09% | -87.25% |
| EPS (TTM) | $-29.59 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $5.50 |
| 52-week low | $4.98 | $1.87 |
| Distance from 52-week high | -39.21% | -35.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +218.15% | +119.03% |
| Average volume | 267.15K | 367.72K |
| Shares outstanding | 7.26M | 57.01M |
| Employees | 29 | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed CUE by 76.2 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
CUE vs WHWK FAQ
Which is bigger, Cue Biopharma or Whitehawk Therapeutics?
Cue Biopharma (CUE) is larger, with a market capitalization of $200.93M compared with $200.67M for Whitehawk Therapeutics (WHWK).
Which stock has performed better over the past year, CUE or WHWK?
WHWK returned +62.91% over the past 12 months, compared with -13.25% for CUE (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.